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Repairing damaged tissues is an essential homeostatic mechanism that enables clearance of dead or damaged cells
after injury, and the maintenance of tissue integrity. However, exaggeration of this process in the lung can lead to the
development of fibrotic scar tissue. This is characterized by excessive accumulation of extracellular matrix (ECM)
components such as fibronectin, proteoglycans, hyaluronic acid, and interstitial collagens. After tissue injury, or a
breakdown of tissue integrity, a cascade of events unfolds to maintain normal tissue homeostasis. Inflammatory
mediators are released from injured epithelium, leading to both platelet activation and inflammatory cell migration.
Inflammatory cells are capable of releasing multiple pro-inflammatory and fibrogenic mediators such as transforming
growth factor (TGF)β and interleukin (IL)-13, which can trigger myofibroblast proliferation and recruitment. The
myofibroblast population is also expanded as a result of epithelial cells undergoing epithelial-to-mesenchymal
transition and of the activation of resident fibroblasts, leading to ECM deposition and tissue remodeling. In the healthy
lung, wound healing then proceeds to restore the normal architecture of the lung; however, fibrosis can develop when
the wound is severe, the tissue injury persists, or the repair process becomes dysregulated. Understanding the
processes regulating aberrant wound healing and the matrix in the chronic fibrotic lung disease idiopathic pulmonary
fibrosis (IPF), is key to identifying new treatments for this chronic debilitating disease. This review focuses primarily on
the emerging role of enzymes in the lungs of patients with IPF. Elevated expression of a number of enzymes that can
directly modulate the ECM has been reported, and recent data indicates that modulating the activity of these enzymes
can have a downstream effect on fibrotic tissue remodeling.
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Fibrotic matrix versus normal matrix
Multiple mechanisms and mediators contribute to an al-
tered ECM in IPF. Components of the ECM are produced
intracellularly by resident cells and secreted into the ECM
where they aggregate with the existing matrix, and can
exert a powerful influence over cell functions. The ECM is
composed of an interlocking mesh of fibrous proteins and
glycosaminoglycans, but the most abundant ECM com-
ponent in most tissues is collagen. The principal collagens
are the interstitial types I and III, which serve to form a fi-
brous network in the interstitium of tissues, and these are
elevated in the parenchyma of patients with IPF [1]. Type
IV collagen is the major component of the basement mem-
brane. This matrix dysregulation and deposition in the* Correspondence: murrayl@medimmune.com
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reproduction in any medium, provided the orlungs of patients with asthma can lead to a thickening in
the basement membrane and directly contribute to disease
via alterations in lung function [2]. In IPF, increased matrix
leads to impaired gaseous exchange, and matrix compo-
nents such as hyaluronic acid can further exacerbate the in-
flammatory milieu seen in the lung and contribute to
disease progression [3] (Figure 1).Matrix-producing cells: fibroblasts and myofibroblasts
The aberrant collagen deposition in the lungs of patients
with IPF derives predominantly from activated fibroblasts
and myofibroblasts. These cells are classically thought to
derive from post-embryonic lung fibroblasts. However, ac-
cumulating data support a bone marrow-derived source
for these cells, called fibrocytes. In experimental models,
fibrocytes contributed to fibrotic remodeling both directly
via ECM production and indirectly through the paracrine
regulation of other fibrogenic cells [4,5]. Fibroblasts maytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and












Figure 1 Schematic outlining the key effector cells that generate transforming growth factor (TGF)β and interleukin (IL)-13 and the
enzymes associated with idiopathic pulmonary fibrosis (IPF). Multiple cell types are found at sites of lung fibrosis. Many are direct producers
of extracellular matrix (ECM), or indirectly promote the generation and deposition of aberrant matrix.
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or endothelial-to-mesenchymal transition [7], although
their precise contribution to α-smooth muscle actin
(α-SMA)-expressing cells remains controversial [8], and
the contribution to disease progression in IPF is not firmly
established.
Fibroblasts play central roles both in the maintenance
of normal tissue function and in the wound healing re-
sponse. The lung is a dynamic organ, often under vary-
ing degrees of motility and stress. By generating ECM,
fibroblasts provide a scaffold for cells and a sink for me-
diators to be able to respond to the rapid changes in
shear force. In the lung, fibroblasts are found in greatest
numbers in the subepithelial layer of the conducting air-
ways and the interstitium of the lung parenchyma, which
puts them in a prime location to interact with the epi-
thelial and endothelial cells.
Fibroblasts and myofibroblasts are metabolically active
cells, capable of synthesizing, secreting, and degrading
ECM components, including collagens, proteoglycans,
tenascin, laminin, and fibronectin. The secretion of
ECM proteins is closesly regulated. Moreover, fibroblasts
generate matrix metalloproteinases (MMPs) and their in-
hibitors, tissue inhibitors of metalloproteinases (TIMPs),
thus controlling tissue architecture and matrix turnover
rates, and contributing to both the initiation and reso-
lution phases following injury. The added contractile
properties of myofibroblasts are also central to controlling
wound healing as well as tissue architecture [9]. In vitro,fibroblast-to-myofibroblast trans-differentiation can be in-
duced by transforming growth factor (TGF)β1 and it has
been hypothesized that TGFβ1 found locally at sites of fi-
brosis trans-differentiate resident fibroblasts into myofi-
broblasts [10,11]. Myofibroblasts are generally absent in
lung parenchyma; however, in IPF, one of the hallmarks of
disease is the presence of α-SMA-positive cells in and
around fibroblastic foci.
IL-13 is another pro-fibrotic mediator that can elicit a
number of fibroblast responses in vitro, as well as dir-
ectly promoting fibrosis in vivo. Fibroblasts isolated from
the lungs of patients with IPF exhibit an increase in
IL-13 receptor expression for both IL-13Rα1 and
IL-13Rα2 [12,13]. Moreover, IPF fibroblasts are hyper-
responsive to IL-13 stimulation in vitro, resulting in en-
hanced collagen production, differentiation to of fibro-
blasts to myofibroblasts, and increased TGFβ expression
[13]. Both T cells and alternatively activated macro-
phages express IL-13 in the IPF lung [14]. Both of these
cell types are found in increased numbers in IPF [15,16].
In vivo mouse models have shown a pro-fibrotic role for
IL-13Rα2 [17], classically thought of as a decoy receptor
for IL-13. However, the relevance of this to human dis-
ease still needs to be determined.
Interestingly, fibroblasts isolated from fibrotic lung tis-
sue are phenotypically different to non-fibrotic fibroblasts
[18-20]. Fibrotic fibroblasts exhibit altered responsiveness
to growth factors and also enhanced chemokine receptor
expression, suggesting a lower tolerance to exogenous
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closely associated with regions of fibroblast accumulation
and proliferation, to the extent that these regions have be-
come a reliable indicator of survival [18-20]. The increased
number of collagen-producing mesenchymal cells seen in
these diseases suggests that these cells are either hyper-
proliferative and/or resistant to apoptosis, and both of these
alterations have been observed in vitro [18,19,21-23]. Col-
lectively, IPF fibroblasts behave more like tumor cells, indi-
cating that they have undergone epigenetic changes, or
have transformed somehow from a normal lung fibroblast
to a disease phenotype.
Remodeling of the matrix and control of matrix turnover
The turnover rates of matrix molecules and the prote-
ases that degrade them are under control of an extensive
network of cytokines, growth factors, proteases, lipid
mediators, and mechanical forces. Fibroblasts synthesize
a host of matrix components driving matrix deposition,
and an abundant number of enzymes regulate matrix
degradation including MMPs and serine proteases [24].
Collagen is also degraded both intracellularly and extra-
cellularly, and the maintenance of tissue homeostasis is
dependent on the regulation of matrix production and
degradation within the tissue. In diseased tissue, it is
clear that this finely balanced process is dysregulated,
leading to tissue destruction and excessive matrix depos-
ition. Mediators involved in this process leading to tissue
fibrosis include locally released polypeptide growth fac-
tors (such as platelet-derived growth factor, epidermal
growth factor, fibroblast growth factor) cytokines such as
TGFβ and the interleukins, and cellular enzymes, which
will be discussed below [25].
MMPs exert proteolytic activities on various proteins in-
cluding many ECM components, and are thus central to
ECM formation [26]. Numerous cell types in the lung are
capable of expressing MMPs, including epithelium, fibro-
blasts, myofibroblasts, and macrophages. These cells have
been shown to be elevated in asthma and chronic ob-
structive pulmonary disease (COPD) [26], as well as in
IPF, where MMP1, MMP2 and MMP9 were shown to be
co-localized to the epithelium surrounding fibrotic lesions,
while increased TIMP2, was also observed suggesting that
the MMP activity may be inhibited and that the fibrotic
region is not degraded [27]. Other work has reported a
role for MMP3, which is elevated in the IPF lung [28].
Overexpression of MMP3 leads to pulmonary fibrosis in
the rat lung, while mice lacking MMP3 are protected [28].
In vitro work suggests a role for MMP3 in the activation
of β-catenin signaling and the induction of epithelial-to-
mesenchymal transition, a process thought to contribute
to the pathogenesis of IPF [29]. IL-13 can directly induce
a number of pro-fibrotic MMPs, including MMP9 and
MMP12 [30], and MMP7 [31], all of which are elevated inthe lungs of patients with IPF. In addition to MMP3,
pro-MMP7 is also elevated in the bronchoalveolar lav-
age fluid of patients with IPF, and is thought to be produced
by the hyperplastic alveolar and metaplastic bronchiolar
epithelial cells, and activated locally in the lung [32]. Mem-
brane type-1 MMP (MT1-MMP or MMP14) has also been
reported to serve as a key effector of type I collagenolytic
activity in pulmonary fibroblasts [33]. Other MMPs have
been associated with the genetic risk of IPF. Polymorphisms
of the MMP-1 promoter have been shown to potentially
confer increased risk for IPF [34]. High-resolution com-
puted tomography (HRCT) and histopathologic evaluation
of fibrosis and tissue destruction in IPF have been associ-
ated with pulmonary emphysema, with expression of
MMP2, MMP7, MMP9, and MT1-MMP by fibroblasts of
myofibroblastic foci being predominant in fibrosis [35].
Other protease activity in IPF
In addition to MMP dysregulation, other enzymes are
known to play a role in IPF. Coagulation proteases, be-
sides their important role in fibrin formation, are now well
recognized to exert pro-fibrotic cellular effects via activa-
tion of protease-activated receptors (PARs) [36]. Mast
cells co-cultured with lung fibroblasts become activated
and release tryptase, which in turn promotes lung fibro-
blast proliferation via PAR-2 [36]. Tryptase-mediated sti-
mulation of fibroblast proliferation occurs via activation of
the protease-activated receptor PAR-2 [37], and more re-
cently a PAR-2 dependency has also been demonstrated
for tryptase induction of collagen and fibronectin syn-
thesis by fibroblasts [38]. Furthermore, those authors hy-
pothesized that the increase in PAR-2 expression observed
in lung fibroblasts from patients with IPF could sensitize
these cells to the effects of mast cell-derived tryptase
[36,38]. PAR-2 is elevated in IPF lungs, and is upregulated
by TGFβ in lung fibroblasts [36]. PAR-2 has also recently
been reported to play a role in aggravating pulmonary fi-
brosis. An absence of PAR-1 signaling in PAR-1 knockout
mice conferred protection in a bleomycin model [39], and
thrombin stimulation of proteoglycan expression is medi-
ated by PAR-1 activation of TGFβ1RI [40]. More recently,
a PAR-1 antagonist attenuated the expression of TGFβ1-
promoted airway remodeling in ovalbumin-allergic rats
[41]. PAR-2 has also recently been reported to play a role
in aggravating pulmonary fibrosis. Mast cells co-cultured
with lung fibroblasts become activated, and release tryp-
tase, which in turn promotes lung fibroblast proliferation
via PAR-2 [38].
Enzymes affecting matrix cross-linking
Enzymes such as transglutaminases (TGs) and lysyl oxi-
dases (LOXs) are also reported to contribute to the patho-
genesis of fibrosis through modification of the ECM. TGs
are a family of nine enzymes that catalyze post-translational
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dation [42]. TG2 (also known as tissue transglutaminase)
is the most abundant and widely expressed member of the
TG family, being present in many cell types including fi-
broblasts, macrophages, smooth muscle cells, hepatocytes,
red blood cells, cardiac myocytes, neurons, chondrocytes,
and kidney cells [43]. TG2 is reported to promote tissue
fibrosis through cross-linking extracellular collagen and
fibronectin, making them more resistant to breakdown
[44], but is known to exert multiple other functions that
may promote fibrosis [45-49]. TG2 has been shown to
promote liver and kidney fibrosis, and to be elevated in
patients with kidney disease [50-54]. TG activity was re-
portedly increased in a rat model of pulmonary fibrosis
[55]. In a mouse model of lung injury induced by bleo-
mycin, bleomycin-induced epithelial damage was me-
diated through TG2, resulting in IL-6 release and the
differentiation of IL-17-producing T cells, with subsequent
inflammatory amplification in the lung [56]. In addition,
the authors reported that fibroblast-derived TG2, acting
downstream of TGFβ, was also important in the effector
phase of fibrogenesis [56]. TG2 knockout mice were pro-
tected from bleomycin-induced lung fibrosis, and TG2 ex-
pression and activity were increased in patients with IPF
versus normal controls [57].
The LOX family is a family of five enzymes that facilitate
the covalent cross-linking of type I collagens via catalysis of
the oxidative deamination reaction between a lysyl or a
hydroxylysyl residue [58,59]. LOXL1 regulates collagen
cross-linking and total collagen levels in angiotensin II-
induced hypertension in rodents [60], has been associated
with renal fibrosis [61], and when overexpressed, induces
cardiac hypertrophy in mice [62]. LOXL2 was reported to
increase collagen accumulation in breast and glioma tu-
mors [63,64], and has been associated with liver fibrosis
[65], as well as IPF [64]. Treatment of mice with an anti-
LOXL2 monoclonal antibody reduced the fibrotic burden
in a model of cancer and lung fibrosis, in part via reduction
in disease-associated fibroblasts. Anti-LOXL2 also led to re-
duced production of growth factors and cross-linked collag-
enous matrix, and also reduced TGFβ signaling, and thus
those authors postulated that LOXL2 could potentially me-
diate fibroblast activation in vivo through its enzymatically
catalyzed cross-linking of fibrillar collagen and correspond-
ing increase in local matrix tension, resulting in activation
of TGFβ1 signaling from the latent complex [64]. Targeting
the cross-linking of collagen is an attractive therapeutic
angle for patients with fibrosis, and indeed, agents blocking
LOXL2 are now entering clinical trials in patients with IPF.
The role of the matrix in promoting fibroblast activation
and inflammation
The ECM, as discussed, is a complex mixture of proteins,
proteoglycans, and glycosaminoglycans, which supportscell and tissue architecture. However, the ECM can also
alter cell adhesion, migration, proliferation/survival, and
differentiation. Recent data have indicated that increased
matrix stiffness increases fibroblast proliferation and con-
tractility [66]. Fibrotic matrix is stiffer than normal lung
matrix (6 to 20 kPa versus 1 kPa) [67]. Moreover, normal
fibroblasts exhibit IPF cell properties when they are sub-
jected to matrices with heightened stiffness, including in-
creased differentiation to myofibroblasts, along with
increased proliferation and resistance to apoptosis [67-70].
Another key pro-fibrotic role for increased matrix stiffness
is the promotion of latent TGFβ activation, whereas com-
pliant matrices have lower levels of TGFβ activation [68].
Previous studies comparing normal and IPF fibroblasts
have been conducted on glass or tissue culture plastic,
and some of the underlying differences in cell responses
may actually be due to the different types of matrix pro-
duced by the cells on different substrates. Therefore, future
studies profiling discrete differences in matrix components
are warranted.
ECM can also directly promote inflammation. Compo-
nents of the ECM, namely hyaluronan and elastin, are
reported to exhibit chemotactic activity on inflammatory
cells, enhance phagocytic function, enhance adhesion of
polymorphonuclear neutrophils (PMNs), induce immune
responses, and change gene expression profiles in in-
flammatory cells [71]. In the initial inflammatory phase
of wound repair, the glycosaminoglycan hyaluronic acid
is abundant, and acts as a promoter of early inflamma-
tion. However, failure to remove ECM degradation prod-
ucts from the site of tissue injury contributes to the
unremitting inflammation and destruction observed in
IPF. Clearance of hyaluronan fragments is thought to be
dependent both on its receptor CD44 and on recogni-
tion by the host via Toll-like receptor (TLR)2 and TLR4
[3]. Hyaluronan-TLR2 and hyaluronan-TLR4 signals
regulate both the innate inflammatory response as well
as the epithelial cell integrity that is crucial for recovery
from acute lung injury [3].
The ECM also plays a role in leukocyte adhesion. Ad-
hesion of PMNs to ECM proteins has been shown to be
important for their migration, and is thought to partici-
pate in PMN recruitment to sites of inflammation. Mi-
gration of PMNs through the parenchyma can be
influenced by the composition of the ECM [72], with
multiple studies demonstrating increased adherence of
PMNs to surfaces coated with fibronectin and collagen
[73]. ECM components such as fibronectin can also act
as chemotactic agents for PMNs, suggesting that local
rates of migration within tissues are potentially regulated
by several different ECM components. Adhesion of
PMNs to collagens is thought to be mediated via the in-
tegrin CD11b/CD18, found on PMNs [74], as shown by
antibody-blocking experiments.
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It is now over three decades since the discovery of TGFβ
[75], and its pleiotropic effects on cell growth, immune
function, and proliferation have been well documented.
Acting as a key pro-fibrotic molecule, TGFβ is a central
stimulator of collagen production in the pathogenesis of
pulmonary fibrosis [76]. The three mammalian isoforms
of the TGFβ family, TGFβ1, TGFβ2, and TGFβ3 are se-
creted as pro-TGFβ forms, covalently bound to a pro-
peptide (latent associated protein (LAP)β1, LAPβ2, and
LAPβ3) in a complex referred to as the small latent com-
plex (SLC). These structures prevent the engagement and
agonism of the active molecule at TGFβ receptors. These
complexes are targeted to structures within the ECM
through latent TGF binding proteins (LTBPs) [77] by as-
sociation with other ECM proteins such as fibronectin,
fibrillin-1, and vitronectin. The majority of cells secrete
TGF as an SLC with LTBP-1 [78,79]. Thus, the large latent
complex represents a storage depot of latent TGFβ for ac-
tivation. Disruption of this process allows the release of
TGFβ1, in a process known as TGFβ1 activation.
Activation of latent TGFβ can occur by multiple mecha-
nisms, and is normally associated with proteolytic degrad-
ation of the LAP or an alteration of LAP confirmation to
allow the activation of TGFβ; for example, bone morpho-
genetic protein-1, multiple MMPs, plasmin, urokinase-
type plasminogen activator (uPA), tissue-type plasminogen
activator, and thrombin [80]. Among proteolytic enzymes,
uPA-mediated activation of plasmin is involved in the acti-
vation of latent TGFβ1 by proteolytic cleavage within the
N-terminal region of LAP [81]. Binding of uPA to its re-
ceptor uPAR can trigger intracellular signal transduction
via interaction with the α5β1 integrin [82], in addition to
focusing plasmin production to release ECM factors and
activate latent TGFβ1 [83,84]. The transmembrane αv
integrins have been shown to bind to and activate latent
TGFβ1 and β3 by binding to arginine-glycine-aspartic acid
(RGD) motifs. This RGD motif is absent in the LAP of
TGFβ2, and consequently no integrin-mediated activation
of TGFβ2 has been described to date. All the αv integrins,
αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8, and the integrins α5β1
and α8β1 bind in this way.
Evidence for this major role for an integrin in TGFβ
activation was first highlighted using β6-deficient mice
that are unable to form the αvβ6 integrin [85] These
mice exhibited an exaggerated inflammatory response
similar to that seen with TGFβ1 and Smad3 knockout
mice [86]. Subsequently, direct evidence of TGF activa-
tion in vivo was demonstrated for αvβ5 [68], αvβ6 [85,]
and αvβ8 [87].
The integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been
shown to activate latent TGFβ1 via two distinct modes
of action [88]. In the case of αvβ8, which is expressed on
normal epithelial cells, fetal fibroblasts, and dendriticand neuronal cells [87], it binds with high affinity to la-
tent TGFβ1 by recognition of the RGD domain, and ac-
tivation is mediated by anchoring of the molecule and
its close proximity with MMP14, bringing about its pro-
teolytic cleavage [89] Fibroblast-specific inducible β8 si-
lencing reduced lung remodeling and TGFβ signaling in
a chronic allergen challenge model [90], demonstrating a
key in vivo function of this integrin.
In the case of αvβ3, αvβ5, and αvβ6, these integrins have
been shown to activate latent TGFβ1 in a proteolysis-
independent manner, by transmission of contractile cell
forces within the LLC. These forces result in deformation
of the latent complex to liberate active TGFβ1 [68,91].
The importance of the role of LTBP-1 as a lever to de-
crease the threshold for TGFβ1 activation has recently
been highlighted [92].
Current clinical approaches measuring and targeting
the matrix
Despite our increasing understanding of the pathology dri-
ving IPF, and the key mechanisms involved in this disease,
another area receiving much interest is how to measure
matrix and collagen turnover clinically in patients, either to
enable identification or to determine disease progression.
HRCT can be used to clinically diagnose and determine the
extent of lung fibrosis; however, repeated HRCT exposure
to a patient who already has lung fibrosis may not be clinic-
ally feasible in the long term. Recently proteolytic gene-
ration of pathological and tissue-specific fragments of
proteins has received increased attention [93] as a method
of identifying potential markers of chronic lung disease in
which matrix dysregulation is a key feature, such as COPD
and IPF.
It has been reported that these protein fragments (also
known as neoepitopes or protein fingerprints) are more
accurate predictors than the unmodified intact proteins
[93]. Examples include a type III collagen fragment gener-
ated by MMPs as a marker for generalized and liver fibro-
sis [92,94], a type II collagen degradation product
generated by MMPs for osteoarthritis and rheumatoid
arthritis [95], and a type I collagen fragment generated by
cathepsin K as a diagnostic tool for measuring and moni-
toring bone resorption [96]. MMP9 and MMP12 have
been associated with elastin degradation, and are impli-
cated in chronic respiratory diseases such as IPF. Recent
work in this field identified an elastin fragment, ELN-441,
which is released by the action of MMP9 and MMP12 on
elastin. This fragment was elevated in the serum of pa-
tients with IPF or COPD, and may represent a novel
method for detecting ECM in IPF and other chronic lung
diseases, following further clinical validation [97].
Another approach that is under development is using
stable isotope labeling techniques in combination with
ultra-high-resolution mass spectrometry. A recent publication
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turnover in vivo using the intratracheal bleomycin
mouse model [98]. Mice were challenged with bleo-
mycin, and given deuterated drinking water 1 week prior
to terminal endpoint, and the percentage of hydroxypro-
line that contained deuterateswater indicated the amount
of new collagen [98]. The results indicated that new colla-
gen generation closely mirrored cell proliferation, and the
initial uptake of deuterated water peaked as early as 1 week
post-bleomycin, when it subsequently declined, whereas
histological fibrosis also peaked 1 week post-bleomycin
but remained elevated throughout the remaining 5 weeks
[98]. Collectively, these results indicated that the fibrosis
observed in this model was initially induced by new colla-
gen deposition and that the continued pathology was not
due to constant collagen turnover, but more to mainten-
ance of the synthesized ECM. Although the intratracheal
bleomycin model has significant limitations and does not
closely resemble clinical IPF, the model has provided in-
sights in to some of the key pathways associated with IPF.
However, if this phenomenon, of an initial burst of ECM
generation that is then maintained resulting in chronic
lung fibrosis, applies to IPF, future anti-fibrotic therapies
should aim to target the maintenance of collagen and not
the initial synthesis.
Conclusions
As described in this review, the matrix provides a num-
ber of pro-fibrotic mechanisms, including direct physio-
chemical activating properties, a sink for pro-fibrotic
and pro-inflammatory mediators, and fostering of ECM-
producing cell survival. Therefore, disrupting the aber-
rant matrix that has accumulated in the IPF lung may
result in a number of pathways being inhibited, and
might provide significant improvements in gas exchange
in the lung, resulting in considerable improvement in
patient mortality and morbidity.
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